Nelson Ambrogio

Senior Vice President and General Manager Women’s Healthcare

Bayer Pharmaceuticals US

Nelson is a highly-respected and dynamic business leader who is dedicated to delivering innovative health care solutions to enhance people’s lives.

As the leader of the Bayer Women’s Healthcare team, he is responsible for Bayer’s leading contraceptive portfolio, with revenues in excess of 900m$ and leading a cross-functional organization of more than 300 team members.
In his previous role, Nelson led the Bayer Pharmaceuticals team in Australia and New Zealand, where he was responsible for the launch of blockbuster drugs including Xarelto (cardiovascular) and Eylea (ophthalmology) and guiding a team of more than 250 people.

Nelson’s career spans more than 20 years with Bayer and Schering in both mature and emerging markets across Latin America, Europe and Australasia. He has held the position of managing director of Bayer Portugal, business unit director General Medicine, Bayer Brazil and assistant to a Bayer Board Member at the company’s headquarters in Germany.
Nelson started his career at Schering in his native Uruguay and was instrumental in the program management of the Bayer-Schering integration in Latin America and Canada.

Chris Coughlin

CMO

Rubius Therapeutics

Dr. Maria Fardis

President and Chief Executive Officer

Lovance Biotherapeutics

Dr. Maria Fardis joined Iovance Biotherapeutics as President and Chief Executive Officer and was appointed to the Board of Directors in 2016. Since joining, the Company has been transformed from an early-stage development company to a company with multiple late-stage programs involving lifileucel and LN-145 for treatment of multiple solid tumors. Dr. Fardis served as the Chief Operating Officer of Acerta Pharma B.V., a clinical-stage biopharmaceutical company, from January 2015 to March 2016, where she worked on the development of Calquence® until the company’s acquisition by AstraZeneca. From 2011 to 2014, she worked at Pharmacyclics, Inc., where she was a key contributor in the creation of a broad clinical program leading to global approvals for Imbruvica® in multiple hematologic malignancies, and where she served as Chief of Oncology Operations and Alliances. Prior to joining Pharmacyclics, from August 2001 to April 2011, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., where she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of Letairis®. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.

Tround Lund

Head of Business Development

N2 Applied

Nicholas Jonsson

Head of Rumen Research

Habro Ltd

Dr Rob Kinley

Chief Scientist, CSIRO

FutureFeed

Frank Wooten

CEO

VENCE